title: Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
abstract: Thioridazine and mesoridazine levels and levels of thioridazine plus metabolites were determined in plasma and red blood cells (RBC) by gas-liquid chromatography (GLC) and spectrofluorometry (SP), respectively, in schizophrenic patients treated with fixed doses of thioridazine. There was wide interpatient variability in RBC:plasma ratios for thioridazine and mesoridazine, a higher ratio of thioridazine to mesoridazine in RBC than plasma, and a higher ratio of GLC total (thioridazine plus mesoridazine), to SP-determined total drug constituents in RBC than in plasma. RBC showed a monotonic increase in drug levels with dose, whereas levels of drug in the plasma began to level off above the 250 mg/day dose. Drug levels 24 h after the acute dose did not predict steady-state blood levels in plasma or RBC.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D002849:Chromatography, Gas; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008653:Mesoridazine / Q000097:blood*; D008875:Middle Aged; D012559:Schizophrenia / Q000097:blood*; D013050:Spectrometry, Fluorescence; D013881:Thioridazine / Q000097:blood*
chemical_list: D008653:Mesoridazine; D013881:Thioridazine